利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

772 条记录 (耗时 0.047 秒)

    ENGINEERED MAMMALIAN CELLS FOR PRODUCTION OF RECOMBINANT PROTEINS
    4.
    发明申请
    ENGINEERED MAMMALIAN CELLS FOR PRODUCTION OF RECOMBINANT PROTEINS 审中-公开
    用于生产重组蛋白的工程化哺乳动物细胞

    公开(公告)号：WO2017186671A1

    公开(公告)日：2017-11-02

    申请号：PCT/EP2017/059719

    申请日：2017-04-25

    申请人： DANMARKS TEKNISKE UNIVERSITET

    发明人： VOLDBORG, Bjørn, Gunnar ,  PEDERSEN, Lasse, Ebdrup

    IPC分类号： C07K14/81 ,  C07K14/78 ,  C07K14/435

    CPC分类号： C12N5/0682 ,  C12N9/6413 ,  C12N15/113 ,  C12N15/62 ,  C12N15/79 ,  C12N2510/02

    摘要： The present invention relates to mammalian cells modified to provide for improved expression of a recombinant protein of interest. In particular, the invention relates to CHO cells and other host cells in which the expression of one or more endogenous secreted proteins has been disrupted, as well as to the preparation, identification and use of such cells in the production of recombinant proteins.

    摘要翻译： 本发明涉及修饰的哺乳动物细胞以提供目标重组蛋白质的改进表达。 具体而言，本发明涉及其中一种或多种内源性分泌蛋白的表达已被破坏的CHO细胞和其他宿主细胞，以及涉及这些细胞在重组蛋白生产中的制备，鉴定和用途。 p>

    MAMMALIAN CELL LINE FOR PROTEIN PRODUCTION AND LIBRARY GENERATION
    5.
    发明申请
    MAMMALIAN CELL LINE FOR PROTEIN PRODUCTION AND LIBRARY GENERATION 审中-公开
    哺乳动物细胞系用于蛋白质生产和文库生成

    公开(公告)号：WO2017174329A1

    公开(公告)日：2017-10-12

    申请号：PCT/EP2017/056373

    申请日：2017-03-17

    申请人： ETH ZURICH

    发明人： REDDY, Sai ,  KELTON, William ,  PAROLA, Cristina ,  MASON, Derek ,  POGSON, Mark

    IPC分类号： C12N5/0781 ,  C12N15/64 ,  C12N15/90

    CPC分类号： C12N5/0635 ,  C12N15/102 ,  C12N15/1037 ,  C12N15/907 ,  C12N2510/00 ,  C12N2510/02 ,  C12Q2521/539

    摘要： According to a first aspect of the invention, a method for the generation of a cell line is provided, comprising the steps of (a) providing a plurality of mammalian B cells, wherein each of the plurality of B cells comprises a transgenic genomic DNA sequence encoding a marker protein inserted into an endogenous immunoglobulin locus comprised in said B cell, and wherein the transgenic genomic DNA sequence is amenable to cleavage by a site directed nuclease, particularly Cas9; (b) replacing the transgenic genomic DNA sequence encoding a marker protein with a second transgenic DNA sequence encoding a protein of interest; (c) sorting B cells based on the presence or absence of the marker protein; and (d) collecting B cells in which the marker protein is absent.

    摘要翻译： 根据本发明的第一方面，提供了用于产生细胞系的方法，包括以下步骤：（a）提供多个哺乳动物B细胞，其中所述多个 B细胞包含编码插入所述B细胞中包含的内源性免疫球蛋白基因座的标记蛋白的转基因基因组DNA序列，并且其中所述转基因基因组DNA序列适于被定点核酸酶特别是Cas9切割; （b）用编码感兴趣蛋白质的第二转基因DNA序列取代编码标记蛋白质的转基因基因组DNA序列; （c）基于标记蛋白质的存在或不存在来分选B细胞; 和（d）收集标记蛋白不存在的B细胞。

    METHODS TO MANIPULATE QUALITY ATTRIBUTES OF POLYPEPTIDES PRODUCED IN CHO CELLS
    6.
    发明申请
    METHODS TO MANIPULATE QUALITY ATTRIBUTES OF POLYPEPTIDES PRODUCED IN CHO CELLS 审中-公开
    调控CHO细胞产生多肽的质量属性的方法

    公开(公告)号：WO2017083224A1

    公开(公告)日：2017-05-18

    申请号：PCT/US2016/060782

    申请日：2016-11-07

    申请人： BRISTOL-MYERS SQUIBB COMPANY

    发明人： TIAN, Jun

    IPC分类号： C12N5/00

    CPC分类号： C12N5/0031 ,  C12N2500/22 ,  C12N2500/32 ,  C12N2510/02 ,  C12P21/005

    摘要： In accordance with the present invention, CHO cells expressing a recombinant polypeptide of interest are grown in media where the amino acids, vitamins, phosphate, lipids and/or antioxidant optimization is utilized to manipulate and/or control the protein quality attributes of the polypeptides. Polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical compositions.

    摘要翻译： 根据本发明，表达感兴趣的重组多肽的CHO细胞在其中利用氨基酸，维生素，磷酸盐，脂质和/或抗氧化剂优化来操纵和/或控制的培养基中生长 多肽的蛋白质质量属性。 根据本发明表达的多肽可以有利地用于制备药物组合物。

    CELLS AND METHOD OF CELL CULTURE
    7.
    发明申请
    CELLS AND METHOD OF CELL CULTURE 审中-公开
    细胞和细胞培养方法

    公开(公告)号：WO2017051347A2

    公开(公告)日：2017-03-30

    申请号：PCT/IB2016/055666

    申请日：2016-09-22

    申请人： PFIZER INC.

    发明人： HILLER, Gregory Walter ,  MITCHELL, Jeffrey Joseph ,  MULUKUTLA, Bhanu Chandra ,  PEGMAN, Pamela Mary

    IPC分类号： C12P21/00 ,  C07K16/00 ,  C07K14/435

    CPC分类号： C07K16/00 ,  C12N2500/32 ,  C12N2500/34 ,  C12N2510/00 ,  C12N2510/02 ,  C12N2511/00 ,  C12P7/40 ,  C12P7/42 ,  C12P7/52 ,  C12P7/56 ,  C12P17/182

    摘要： The invention relates to a method of cell culture where the cells are modified to reduce the level of synthesis of growth and/or productivity inhibitors by the cell. The invention also relates to a method of cell culture for improving cell growth and productivity, in particular in fed-batch culture of mammalian cells at high cell density. The invention further relates to a method of producing cells with improved cell growth and/or productivity in cell culture and to cells obtained or obtainable by such methods.

    摘要翻译： 本发明涉及细胞培养方法，其中细胞被修饰以降低细胞的生长和/或生产抑制剂的合成水平。 本发明还涉及用于改善细胞生长和生产力的细胞培养方法，特别是在高细胞密度下哺乳动物细胞的补料分批培养中。 本发明还涉及一种生产细胞培养细胞生长和/或生产力的细胞和通过这些方法获得或获得的细胞的方法。

    OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS
    8.
    发明申请
    OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS 审中-公开
    优化CRISPR / CAS9系统和干细胞基因编码方法

    公开(公告)号：WO2016182959A8

    公开(公告)日：2017-03-30

    申请号：PCT/US2016031366

    申请日：2016-05-06

    申请人： EDITAS MEDICINE INC

    发明人： GORI JENNIFER LEAH

    IPC分类号： C12N15/87 ,  A61K35/28 ,  C07K14/315 ,  C12N5/0789 ,  C12N9/22

    CPC分类号： C07K14/315 ,  A01K67/0271 ,  A01K2207/12 ,  A61K35/28 ,  C12N5/0647 ,  C12N9/22 ,  C12N15/102 ,  C12N15/87 ,  C12N2500/36 ,  C12N2501/999 ,  C12N2510/02

    摘要： The methods and compositions described herein surprisingly increase CRISPR/Cas- mediated gene editing in stem cells by transiently treating the cells with a stem cell viability enhancer prior to and/or after contacting the cells with one or more CRISPR/Cas9 components. Further, this treatment also surprisingly results in increased engraftment of the stem cells into the target tissue of a subject. The present disclosure also provides one or more modified CRISPR/Cas9 components which, when used in combination with the stem cell viability enhancer, further increases the frequency of gene editing in stem cells, increases stem cell viability, and increases stem cell engraftment.

    摘要翻译： 本文描述的方法和组合物令人惊奇地增加干细胞中CRISPR / Cas介导的基因编辑，通过在细胞与一种或多种CRISPR / Cas9组分接触之前和/或之后，用干细胞活力增强剂短暂处理细胞。 此外，该治疗也令人惊讶地导致干细胞移植到受试者的靶组织中的增加。 本公开还提供了一种或多种修饰的CRISPR / Cas9组分，当与干细胞活力增强剂组合使用时，进一步增加干细胞中基因编辑的频率，增加干细胞活力并增加干细胞移植。